Aspects of the future of therapy for patients infected with a high viral load and interferon-resistant subtype of HCV

Matsumoto, Akihiro; Kiyosawa, Kendo
September 2002
Journal of Gastroenterology;2002, Vol. 37 Issue 9, p766
Academic Journal
Editorial. Focuses on the treatment of patients infected with a high viral load and interferon-resistant subtype of hepatitis C virus. Importance of continuous exposure to and tissue accumulation of ribavirin for sustained virological response to combination therapy; Efficacy and safety of consensus interferon in treatment of chronic hepatitis C; Prolongation of plasma half-life.


Related Articles

  • The "Hit Hard And Hit Earl" Strategy To Treat Chronic Hepatitis C. Barreiros, Ana Paula; Schlaak, Jörg; Gerken, Guido; Galle, PR; Löhr, Hanns // Internet Journal of Gastroenterology;2003, Vol. 2 Issue 2, p22 

    Daily dosed interferon-alpha may prevent mutations of the hepatitis C virus (HCV) quasi-species and may therefore be more efficient in the treatment of chronic hepatitis C than the conventional therapy regimen given three times a week. The drop of viral load in the initial therapy phase has been...

  • The new era of hepatitis C treatment: still the tip of the iceberg? GASBARRINI, A.; PONZIANI, F. R.; ANNICHIARICO, B. E.; SICILIANO, M.; CRAXÌ, A. // European Review for Medical & Pharmacological Sciences;Sep2013, Vol. 17 Issue 17, p2271 

    The author discusses the new age of hepatitis C treatment. The revolution of hepatitis C virus (HCV) infection treatment began in the early 1990s, with the introduction of interferon (IFN) alpha, but the optimal results have been attained in the recent years. Hepatitis C, far from the...

  • Therapy of Acute Hepatitis C: A Review of Literature. Santantonio, T.; Fasano, M. // Current Pharmaceutical Design;Jun2008, Vol. 14 Issue 17, p1686 

    The goal of treatment for acute hepatitis C patients is to eradicate the virus in the early phase of infection, thus preventing progression to chronicity. Early interferon (IFN) monotherapy has been shown to significantly reduce this risk, and therefore it has been recommended by international...

  • Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).  // Virology Journal;2012, Vol. 9 Issue 1, p18 

    The article focuses on a study conducted to examine the response of standard interferon therapy in chronic Hepatitis C Virus (HCV) patients of Khyber Pakhtunkhwa (KPK) province in Pakistan. The study involved 174 patients who were given standard interferon with ribavirin after confirmation of...

  • The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C. Bellanti, F.; Vendemiale, G.; Altomare, E.; Serviddio, G. // Clinical & Developmental Immunology;2012, p1 

    Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to...

  • Interferon α/peginterferon α-2a.  // Reactions Weekly;11/15/2008, Issue 1228, p24 

    The article describes three case reports of successful tryptophan add-on or monotherapy of hepatitis C and IFN alpha-associated mood disorders. The patients involved patients who developed depression while receiving interferon α and peginterferon α2a for hepatitis C. It is observed that...

  • Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1. Chee-Kin Hui; Man-Fung Yuen; Sablon, Erwin; Chan, Annie On-On; Wong, Benjamin Chun-Yu; Ching-Lung Lai // Journal of Infectious Diseases;4/1/2003, Vol. 187 Issue 7, p1071 

    Compares the effect of interferon and ribavirin therapy in hepatitis C virus (HCV) genotypes 1 and 6. Patients with seropositive anti-HCV, persistently elevated alanine transaminase levels and detectable HCV RNA; Sustained virological response (SVR) in a number of patients with genotype 6 and...

  • Association of CTLA4 Polymorphisms with Sustained Response to Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Infection. Yee, Leland J.; Perez, Kevin A.; Jianming Tang; van Leeuwen, Dirk J.; Kaslow, Richard A. // Journal of Infectious Diseases;4/15/2003, Vol. 187 Issue 8, p1264 

    Examines the associations of cytotoxic T lymphocyte antigen-4 single-nucleotide polymorphisms at promoter site -318 and exon-1 site 49 with clearance of hepatitis C virus after treatment with combination interferon-alpha plus ribavirin. Persistence of comparably strong associations after...

  • Simeprevir for the treatment of hepatitis C virus infection. Izquierdo, Laure; Helle, François; François, Catherine; Castelain, Sandrine; Duverlie, Gilles; Brochot, Etienne // Pharmacogenomics & Personalized Medicine;Aug2014, Vol. 7, p241 

    Simeprevir (TMC435, Olysioâ„¢), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics